Trianz Solutions Announces Availability of Acceliant eClinical Suite V6.1
Trianz Solutions announced that Version 6.1 of the Acceliant™ eClinical Suite for web-based clinical trial management and data collection is in General Availability (GA) status. The Acceliant eClinical Suite is a comprehensive, web-based, end-to-end platform with the unique ability to integrate electronic data capture, and data and document management with traditional paper-based processes for Clinical Trials. Acceliant’s innovatively designed functions enable fast, efficient, standards compliant clinical trial design, execution and management.
A key productivity enhancement in Acceliant V6.1 provides trial builders the ability to define and import CRF metadata in commonly available formats. This allows data managers and their staff to collaboratively design and deploy CRF’s hours after approval. In addition, changes to specifications can be re-imported with ease. This feature adds to the existing features for import of edit checks and test data, thus further reducing CRF development and deployment time.
Additionally, V6.1 enhances
• Support for Phase IV studies by increasing scalability and performance on a single server compared to previous versions of Acceliant.
• Export of extremely large data sets with on-the-fly compression
• Features to customize and improve import performance
• Reporting with additional report templates and use of custom filters in reports
• Table controls with custom row level reports (e.g. Adverse Events)
• The notification subsystem to notify user groups on subject events, edit check failures and other statuses in Acceliant.
• Computer based training capabilities
The Acceliant eClinical Suite also includes integrated modules for coding, document management, and trial administration to unmask the clinical trial process and provide clients complete visibility and access into the management of their clinical trial data. Acceliant supports Phase I to Phase IV trials, Registries, and post-marketing studies.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
